Key Highlights

  • Fulgent Genetics (NASDAQ:FLGT) was trading up 19.64% at USD 22.33 on Friday, November 6, 2026, after third-quarter results released following the close on November 5.
  • Third-quarter Revenue rose about 8% to USD 90.4 million from USD 84.1 million, while the GAAP net loss widened to USD 13.2 million, or USD 0.48 per share.
  • Full-year 2026 revenue guidance of USD 330 million to USD 340 million was maintained, and the non-GAAP net loss outlook improved to USD 46 million to USD 50 million.
  • Cash and securities were USD 652.4 million at September 30, 2026, and the company has spent USD 64.1 million on Buybacks so far this year.

Revenue Growth and a Better Loss Outlook Meet a Wider Loss

Fulgent Genetics (NASDAQ:FLGT) reported third-quarter 2026 results on November 5, 2026, after the market close, and the shares were trading up 19.64% at USD 22.33 on the screener the next day. Revenue was USD 90.4 million, up about 8% from USD 84.1 million. The GAAP net loss was USD 13.2 million, against USD 0.21 per share a year earlier, and the non-GAAP net loss was USD 2.4 million, or USD 0.09 per share, against non-GAAP income of USD 4.5 million. Adjusted EBITDA was a loss of USD 7.5 million, against a profit of USD 0.7 million. The headline loss therefore does not explain the rise on its own.

Collections, Spending Discipline and Guidance Tweaks

Fulgent runs a laboratory services Business and a therapeutic development business. The CFO attributed the quarter to improved collection rates and progress on a billing system issue, and management credited disciplined spending for a better non-GAAP loss outlook. Full-year revenue guidance was held at USD 330 million to USD 340 million, but the non-GAAP net loss is now expected at about USD 46 million to USD 50 million. Year-end cash and securities are expected near USD 630 million, assuming no further near-term repurchases. The company reported a reduction of 4.1 million shares from buybacks this year. Those moves on cash and cost, rather than on growth, are the likely reading, though no company statement on the price move exists. Weighted share counts also fell as buybacks retired shares, which supports per-share figures.

Gross Margin Compression and the Risks Behind the Rally

Margins moved the wrong way. GAAP gross margin fell to 35.3% from 42.2%, and cost of revenue rose to USD 58.5 million from USD 48.6 million, while selling and Marketing expense rose to USD 15.6 million from USD 11.6 million. The GAAP operating loss was USD 22.5 million. Cash and securities of USD 652.4 million, split between USD 86.8 million of cash and USD 565.5 million of marketable securities, give the company room to absorb losses. Risks include collection rates reversing, reimbursement pressure, and a stock that already gained 19.64% in one session, a move that can retrace if the next quarter shows weaker margins.

Where Things Stand

The rise looks like a reaction to the cash and loss outlook rather than to a clean beat. Fulgent Genetics (NASDAQ:FLGT) gained 19.64% to USD 22.33 on the screener after a quarter with revenue growth of about 8%, a better non-GAAP loss range and USD 652.4 million of cash and securities, even though the GAAP loss widened and gross margin fell to 35.3%. That reading is inferred from the release, not stated by the company. The next tests are fourth-quarter margins whether collections keep improving, how the billing system issue is resolved and whether the therapeutic development spend of about USD 21 million this year delivers progress on its programs.